Portfolio Case
Chipscreen Biosciences
2018 - 08 - 20
Chipscreen Biosciences
Epidaza (Chidamide) is the first marketed innovative drug developed by a Chinese pharmaceutical company. As an oral HDAC inhibitor, Epidaza targets recurrent peripheral T cell lymphoma. Meanwhile, it can also treat other hematological cancer, solid tumor and even HIV combined with other drugs. Multiple clinical trials are conducted in the U.S., Japan, China and Taiwan.
more
Ascentage Pharma
2018 - 08 - 20
Ascentage Pharma
Ascentage is a globally-focused, clinical-stage biopharma developing novel therapies for cancers, hepatitis B & age-related diseases. Its expertise is in developing inhibitors of protein-protein interactions (PPIs) to restore apoptosisor programmed cell death. There are seven drug candidates in Phase I or II clinical trials in the U.S., Australia and China, including a novel Bcl-2/Bcl-xL inhibitor as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs).
more
Frontier Biotech
2018 - 08 - 20
Frontier Biotech
Frontier Biotech is a research-based, clinical stage pharmaceutical company founded in 2002. The management team have extensive business and development experiences in the US and China pharma/biotech industry. Frontier Biotech leverages China's large patient population, and rapid growing economy and pharmaceutical market, develops innovative pharmaceutical products with worldwide IP protection. Frontier Biotech develops Albuvirtide, the first long-acting anti-HIV drug worldwide, which has been approved by CFDA and launched in the third quarter of 2018. The company is dedicated in the discovery, development and commercialization of innovative therapeutic products for unmet medical needs and under-served patients.
more
Lifotronic
2018 - 08 - 20
Lifotronic
Established in 2008, Lifotronic is a professional international medical enterprise dedicated to developing better products and services with outstanding value for people’s health and life, fostering a culture of dedication, professionalism, integrity and innovation. As a professional medical device manufacturer, Lifotronic specializes in the development, manufacturing and marketing of Bedside Treatment and Diagnostic products.
more
Healthgen Biotech
2018 - 08 - 20
Healthgen Biotech
Healthgen Biotechnology Corp. (Healthgen Biotech) is a private company founded in 2006. It focuses on developing, manufacturing and marketing a series of environmental friendly and safe products by using the State-of-the-Art platform called OryzHiExp, having high capacity to express proteins or small peptides in the rice grain.Using the OryzHiExp platform, Healthgen Biotech maximizes the innovative animal-free product development opportunities for clients and partners. Its cost-effective expression capability made it as a breakthrough expression platform. Healthgen Biotech has achievements in developing and commercializing products, such as OsrHSA, OsrbFGF, OsrIGF-1, OsrEGF, OsrLF, OsrAAT. Meanwhile, it can provide customized protein or peptides expression services.
more
Aridis Pharmaceuticals, Inc.
2018 - 08 - 21
Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases. Complementing the product pipeline is a disruptive platform technology to discover rare, potent human monoclonal antibodies from patients. Its scientists and leadership team have a proven track record of innovation and successful drug development stewardship of therapeutic candidates from early discovery to commercial implementation.Aridis has been listed on Nasdaq in August 2018.
more
Centrexion Therapeutics
2018 - 08 - 21
Centrexion Therapeutics
Centrexion Therapeutics is transforming the treatment of chronic pain by advancing one of the largest, exclusively pain-focused clinical pipelines of novel, non-opioid therapies. It aims to bridge the safety and efficacy gaps in current approaches to chronic pain management.The pipeline represents the mission to tackle the problem of chronic pain head on by developing treatments that act at new or emerging pharmacological targets and delivering them in ways that best address the particular type of chronic pain. This includes a topical gel, a joint or deeper tissue injection, a spinal delivery, and three separate oral treatments.
more
Apexigen
2018 - 08 - 21
Apexigen
Apexigen is a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. The company's pipeline of immuno-oncology therapeutic candidates is led by the APX005M program, which is currently in clinical development.Apexigen'sAPXiMAB™ technology platform enables Apexigen and its partners to discover high-quality antibody drug candidates against challenging disease targets. Apexigen has established eight corporate partnerships: five of these partners are conducting clinical trials of antibodies discovered using the APXiMAB™ platform.
more
KBP Biosciences
2018 - 08 - 21
KBP Biosciences
KBP is a world-class biotechnology research & development organization dedicated to providing innovative therapies for unmet medical needs.Its integrated discovery and development platform enable the company to efficiently bring new drugs from bench to clinics around the world.KBP focuses its resources on therapeutic areas where there are significant unmet medical needs. The key areas of interest include Cardiovascular, Infectious Disease, Respiratory, Inflammatory and Autoimmune diseases.
more
Resverlogix
2018 - 08 - 21
Resverlogix
Resverlogix is a late-stage clinical biotechnology company dedicated to improving and saving the lives of patients with high-risk cardiovascular disease, diabetes mellitus, and chronic kidney disease.Resverlogix is developing an advanced epigenetic drug called apabetalone for the treatment of high-risk cardiovascular disease patients who also have type 2 diabetes mellitus and low high-density lipoprotein (HDL). The current standard of care for these patients is administration of statins, of which, the two most common are Lipitor and Crestor. Despite maximized use, statins only manage approximately 30 percent of cardiovascular events. The opportunity for apabetalone is in addressing the huge remaining unmet medical need that can be attributed to other unmanaged risk factors such as inflammation. When used in combination with current treatments, apabetalone could address the 70 percent of unmet need in this patient group, specifically the residual inflammatory risk.
more
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务